Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,064,068
  • Shares Outstanding, K 108,060
  • Annual Sales, $ 5,872 M
  • Annual Income, $ 1,199 M
  • 36-Month Beta 1.12
  • Price/Sales 6.95
  • Price/Cash Flow 24.22
  • Price/Book 5.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 5.03
  • Number of Estimates 1
  • High Estimate 5.03
  • Low Estimate 5.03
  • Prior Year 3.32
  • Growth Rate Est. (year over year) +51.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
367.73 +8.37%
on 10/11/18
410.00 -2.80%
on 10/01/18
+6.35 (+1.62%)
since 09/14/18
3-Month
360.72 +10.48%
on 07/18/18
416.49 -4.31%
on 08/30/18
+33.77 (+9.26%)
since 07/16/18
52-Week
281.89 +41.37%
on 05/09/18
448.57 -11.16%
on 10/17/17
-47.16 (-10.58%)
since 10/16/17

Most Recent Stories

More News
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary...

SAN : 4.97 (+1.02%)
REGN : 398.52 (+5.55%)
SNY : 44.35 (+2.12%)
Government Initiatives to Boost Global Atopic Dermatitis Market by 8.2% CAGR till 2023 – Asserts MRFR

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 187.99 (+2.75%)
ALPMF : 16.9100 (-2.87%)
NVS : 85.72 (+3.09%)
REGN : 398.52 (+5.55%)
PFE : 43.93 (+1.88%)
BMY : 57.83 (+0.38%)
Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps

Dupixent significantly reduced nasal polyp size, nasal congestion severity and need for systemic corticosteroids and/or surgery

REGN : 398.52 (+5.55%)
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European...

REGN : 398.52 (+5.55%)
Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2018 financial and operating results on Tuesday, November 6, 2018, before the U.S. financial markets...

REGN : 398.52 (+5.55%)
Uptrend Call Working As Regeneron Pharm Stock Rises 29.8% (REGN)

SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on June 4th, 2018 at $309.88. In approximately 4 months, Regeneron Pharm has returned 29.82% as of today's recent price of $402.29.

REGN : 398.52 (+5.55%)
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

GILD : 76.31 (+4.85%)
GERN : 1.84 (+10.84%)
REGN : 398.52 (+5.55%)
AMGN : 202.34 (+3.45%)
SNY : 44.35 (+2.12%)
ALXN : 127.70 (+5.11%)
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer

Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.

AZN : 39.08 (+4.30%)
MRK : 71.22 (+2.53%)
REGN : 398.52 (+5.55%)
SNY : 44.35 (+2.12%)
FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who...

REGN : 398.52 (+5.55%)
SNY : 44.35 (+2.12%)
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

Libtayo is the third anti-PD-1 approved in the U.S.

REGN : 398.52 (+5.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 411.52
1st Resistance Point 405.02
Last Price 398.52
1st Support Level 386.40
2nd Support Level 374.28

See More

52-Week High 448.57
Last Price 398.52
Fibonacci 61.8% 384.90
Fibonacci 50% 365.23
Fibonacci 38.2% 345.56
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar